Leap Therapeutics, Inc. (NASDAQ:LPTX) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

On May 12, 2017, Leap Therapeutics, Inc. issued a press release
announcing its financial results for the first quarter ended
March 31, 2017 and that an investigator-initiated clinical trial
of DKN-01 will be conducted in patients with advanced
hepatocellular carcinoma (HCC) at the University Medical Center
of the Johannes Gutenberg-University Mainz in Germany. The full
text of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the
information in Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure

The disclosure in Item 2.01 of this Current Report on Form 8-K is
incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the
information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

About Leap Therapeutics, Inc. (NASDAQ:LPTX)

Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .

Leap Therapeutics, Inc. (NASDAQ:LPTX) Recent Trading Information

Leap Therapeutics, Inc. (NASDAQ:LPTX) closed its last trading session down -0.53 at 7.20 with 2,084 shares trading hands.